Obesity (Silver Spring) 14 (2), 194198 (2006)
In contrast, GLP-1 injectables, such as Ozempic, Wegovy, Zepbound, and Mounjaro, are prescription medications that help with weight loss in obesity and diabetes management
Regulatory submissions are anticipated in late 2025 for obesity and in 2026 for type 2 diabetes [75]
These medications include semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), liraglutide (Victoza, Saxenda), and tirzepatide (Mounjaro, Zepbound)though tirzepatide is technically a dual GIP/GLP-1 receptor agonist, not a pure GLP-1 agonist
Medications such as orlistat (a pancreatic lipase inhibitor) carry FDA approval for ages 12 and up and represent a lower-risk starting point
As exendin(9-39) does not completely eliminate GLP-1 action, we tested the acute glucoregulatory actions of metformin in mice with genetic disruption of one or both incretin receptors